Abstract
BackgroundImmune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs). Although the incidence and prevalence of irAEs have been well characterized in the literature, less is known about the...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have